(Q33448825)

26 July 2017

title

Effects of long-term PPI treatment on producing bowel symptoms and SIBO. (English)

1 reference

26 July 2017

Alba Rocco

3

0 references

Giovanni Sarnelli

Giovanni Sarnelli

6

0 references

Marco Romano

Marco Romano

7

0 references

Gerardo Nardone

Gerardo Nardone

8

0 references

Rosario Cuomo

Rosario Cuomo

5

0 references

Debora Compare

1

Debora Compare

1 reference

26 July 2017

Loredana Pica

2

1 reference

26 July 2017

Francesco De Giorgi

4

1 reference

26 July 2017

publication date

3 December 2010

1 reference

European Journal of Clinical Investigation

26 July 2017

published in

1 reference

26 July 2017

volume

41

1 reference

26 July 2017

issue

4

1 reference

26 July 2017

page(s)

380-386

1 reference

Gastroesophageal reflux symptoms in a Danish population: a prospective follow-up analysis of symptoms, quality of life, and health-care use.

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2010.02419.X

Prevalence of symptoms suggestive of gastro-oesophageal reflux disease in an adult population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2010.02419.X

Prevalence and impact of symptoms suggestive of gastroesophageal reflux disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2010.02419.X

Comparable efficacy of pantoprazole and omeprazole in patients with moderate to severe reflux esophagitis. Results of a multinational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2010.02419.X

40 mg pantoprazole and 40 mg esomeprazole are equivalent in the healing of esophageal lesions and relief from gastroesophageal reflux disease-related symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2010.02419.X

Once-daily pantoprazole 40 mg and esomeprazole 40 mg have equivalent overall efficacy in relieving GERD-related symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2010.02419.X

Management strategies for gastroesophageal reflux disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2010.02419.X

Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2010.02419.X

Mortality study of 18 000 patients treated with omeprazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2010.02419.X

Overutilization of proton pump inhibitors: a review of cost-effectiveness and risk [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2010.02419.X

A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2010.02419.X

Systematic review of the risk of enteric infection in patients taking acid suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2010.02419.X

Long-term proton pump inhibitor therapy and risk of hip fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2010.02419.X

Review article: proton pump inhibitors and bacterial overgrowth

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2010.02419.X

Relationship between gastric secretion and infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2010.02419.X

Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2010.02419.X

Effectiveness of proton pump inhibitors in nonerosive reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2010.02419.X

Functional bowel disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2010.02419.X

The endoscopic assessment of esophagitis: a progress report on observer agreement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2010.02419.X

Studying the overlap between IBS and GERD: a systematic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2010.02419.X

Altered rectal perception is a biological marker of patients with irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2010.02419.X

Bacterial overgrowth and irritable bowel syndrome: unifying hypothesis or a spurious consequence of proton pump inhibitors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2010.02419.X

Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2010.02419.X

Intragastric nitrites, nitrosamines, and bacterial overgrowth during cimetidine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2010.02419.X

Effects of one year's treatment with ranitidine and of truncal vagotomy on gastric contents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2010.02419.X

Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2010.02419.X

Duodenal bacterial overgrowth during treatment in outpatients with omeprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2010.02419.X

Altered bowel function and duodenal bacterial overgrowth in patients treated with omeprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2010.02419.X

Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2010.02419.X

10.1111/J.1365-2362.2010.02419.X

21 January 2018

Identifiers

DOI

1 reference

26 July 2017

1 reference